We are pleased to congratulate EnteroBiotix, on their milestone in their journey towards revolutionising healthcare for patients battling gut-related ailments. The leading clinical-stage biotechnology company has successfully closed a £27 million funding round, with support from new and existing investors.
The funding will be used for the advancement of their lead product candidate EBX-102-02, as they begin clinical trials on Phase 2, which will target Irritable Bowel Syndrome (IBS) in collaboration with the esteemed Functional Gut Clinic. Additionally, this will fuel the progression of EnteroBiotix’s work with addressing a spectrum of conditions stemming from gut microbiome dysbiosis, including liver cirrhosis and hepatic encephalopathy (HE).
Craig Thomson, Partner, said: “It has been a pleasure for our Microbiome-focus IP team to work with EnteroBiotix and we all take great pride in assisting them with securing a strong, dynamic IP portfolio to protect its assets, which plays an important role in driving innovation. We look forward to seeing the positive developments this advancement will bring.”
Click the button below to find out more.
